$8.06−0.47 (−5.45%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Novavax (NVAX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
2 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 43% below its peak, net margin 39.2%; free cash flow runs at −57% of net income. Check the accrual gap. Worth your attention in FY25: Share count (+132.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲64.7%
1,123.5
FY21→FY25CAGR −0.5%/yr
Net income ($M)—
440.3
FY21→FY25CAGR —
Free cash flow ($M)▼146.3%
−251.0
FY21→FY25CAGR —
Diluted EPS—
2.58
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+132.7%
74.4mn → 173.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$6.4M
−56.4% YoY in FY25 · 0.6% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
39¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin 39.2% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 411.6 | 1,123.5 | 682.2 | 983.7 | 1,981.9 | 1,146.3 | ▲64.7% | −0.5% |
Cost of revenue | 90.5 | 73.0 | 202.7 | 343.8 | 902.6 | 0.0 | ▼64.0% | −56.7% (22→25) |
Gross profit | 321.1 | —A | 479.4 | 639.9 | 1,079.2 | 1,146.3 | — | — |
Research & development | 294.5 | 342.3 | 391.2 | 737.5 | 1,235.3 | 2,534.5 | ▼12.5% | −39.4% |
Selling, general & admin | 113.2 | 157.5 | 337.2 | 468.9 | 488.7 | 298.4 | ▼53.3% | −14.8% |
Total operating expenses | 408.5 | 597.6 | 728.4 | 1,206.4 | 1,724.0 | 2,832.9 | ▼17.9% | −32.2% |
Operating incomefeeds ROC rank | −87.4 | 452.8 | −248.9 | −566.5 | −644.7 | −1,686.6 | — | — |
Other income, net | 15.5 | −10.6 | 72.3 | 23.5 | −8.9 | −28.0 | — | — |
Pretax income | −71.9 | 442.2 | −176.6 | −543.0 | −653.6 | −1,714.5 | — | — |
Income tax | 4.8 | 1.9 | 10.9 | 2.0 | 4.3 | 29.2 | ▼82.9% | −49.7% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | −76.7 | 440.3 | −187.5 | −545.1 | −657.9 | −1,743.8 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.29 | 2.58 | −1.23 | −5.41 | −8.42 | −23.44 | — | — |
Diluted shares (mn) | 164.92 | 173.10 | 152.19 | 100.77 | 78.18 | 74.40 | ▲13.7% | +23.5% |
| Margins | ||||||||
Gross margin71st pct in Healthcare | 78.0% | —A | 70.3% | 65.1% | 54.5% | 100.0% | — | — |
Operating margin | −21.2% | 40.3% | −36.5% | −57.6% | −32.5% | −147.1% | ▲76.8pp | +187.4pp |
Net margin23rd pct in Healthcare | −18.6% | 39.2% | −27.5% | −55.4% | −33.2% | −152.1% | ▲66.7pp | +191.3pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Novavax's revenue last fiscal year?
Novavax reported revenue of $1,123.5M in fiscal 2025, up 64.7% from fiscal 2024.
What was Novavax's net income?
Novavax reported net income of $440.3M in fiscal 2025, a net margin of 39.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

